CD274 and neoplasm: They found greater overall OS in the tislelizumab treatment group compared to the placebo group in patients with a PD-L1 tumor area positivity (TAP) score of ≥5% (median 15.0 vs 12.9 months; HR = 0.80; 95% CI, 0.70–0.92; P = 0.001).